Log in

Cerus Stock Forecast, Price & News

+0.05 (+0.81 %)
(As of 09/22/2020 12:00 AM ET)
Today's Range
Now: $6.24
50-Day Range
MA: $6.57
52-Week Range
Now: $6.24
Volume817,554 shs
Average Volume1.86 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.
Read More
Cerus logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:CERS



Sales & Book Value

Annual Sales$74.65 million
Book Value$0.41 per share


Net Income$-71,240,000.00


Market Cap$1.04 billion
Next Earnings Date11/4/2020 (Estimated)
+0.05 (+0.81 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cerus (NASDAQ:CERS) Frequently Asked Questions

How has Cerus' stock been impacted by COVID-19?

Cerus' stock was trading at $4.76 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CERS stock has increased by 31.1% and is now trading at $6.24.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cerus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cerus

When is Cerus' next earnings date?

Cerus is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cerus

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The biotechnology company had revenue of $21.50 million for the quarter, compared to analysts' expectations of $21.50 million. Cerus had a negative net margin of 83.78% and a negative return on equity of 76.83%.
View Cerus' earnings history

What guidance has Cerus issued on next quarter's earnings?

Cerus updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $89-93 million, compared to the consensus revenue estimate of $112.8 million.

What price target have analysts set for CERS?

4 equities research analysts have issued twelve-month price objectives for Cerus' shares. Their forecasts range from $6.50 to $9.00. On average, they expect Cerus' share price to reach $7.63 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Cerus

Are investors shorting Cerus?

Cerus saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 11,430,000 shares, an increase of 15.2% from the August 15th total of 9,920,000 shares. Based on an average daily volume of 1,900,000 shares, the days-to-cover ratio is currently 6.0 days.
View Cerus' Short Interest

Who are some of Cerus' key competitors?

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Opko Health (OPK), Pfizer (PFE), Immunomedics (IMMU), ACADIA Pharmaceuticals (ACAD), Novavax (NVAX) and Advanced Micro Devices (AMD).

Who are Cerus' key executives?

Cerus' management team includes the following people:
  • Mr. William M. Greenman, Pres, CEO & Director (Age 52)
  • Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 75)
  • Mr. Kevin D. Green, VP of Fin. & CFO (Age 47)
  • Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 48)
  • Dr. Richard J. Benjamin, Chief Medical Officer (Age 59)

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.54%), Vanguard Group Inc. (5.31%), Paradigm Capital Management Inc. NY (0.92%), Peregrine Capital Management LLC (0.88%), Nuveen Asset Management LLC (0.81%) and Intrinsic Edge Capital Management LLC (0.72%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, Timothy L Moore and William Mariner Greenman.
View institutional ownership trends for Cerus

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Pier Capital LLC, Intrinsic Edge Capital Management LLC, Silvercrest Asset Management Group LLC, Peregrine Capital Management LLC, FMR LLC, FMR LLC, Paradigm Capital Management Inc. NY, and Lesa Sroufe & Co. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Gail Schulze, Kevin Dennis Green, Richard J Benjamin, Timothy B Anderson, and William Mariner Greenman.
View insider buying and selling activity for Cerus

Which institutional investors are buying Cerus stock?

CERS stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., UBS Group AG, Marshall Wace North America L.P., EAM Investors LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, and Cubist Systematic Strategies LLC. Company insiders that have bought Cerus stock in the last two years include Timothy L Moore, and William Mariner Greenman.
View insider buying and selling activity for Cerus

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.24.

How big of a company is Cerus?

Cerus has a market capitalization of $1.04 billion and generates $74.65 million in revenue each year. The biotechnology company earns $-71,240,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Cerus employs 240 workers across the globe.

What is Cerus' official website?

The official website for Cerus is www.cerus.com.

How can I contact Cerus?

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.